Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 61 to 75 of 108 results for melanoma

  1. Monitoring and response biomarkers: Can biomarkers accurately classify recurrence, progression and response to treatment?

    analysis of melanoma tissue samples. Full details of the evidence and the committee's discussion are in evidence review A: genetic...

    Research recommendation
    Published
    4 August 2022

  2. Pembrolizumab with epacadostat for untreated malignant melanoma [ID1423]

    Discontinued Reference number: GID-TA10330

    Technology appraisal guidance
    Discontinued

  3. Temozolomide for the treatment of advanced and metastatic melanoma [ID316]

    Discontinued Reference number: GID-TAG401

    Technology appraisal guidance
    Discontinued

  4. Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer (TA904)

    Evidence-based recommendations on pembrolizumab (Keytruda) with lenvatinib (Lenvima) for treating advanced or recurrent endometrial cancer in adults.

    Technology appraisal guidance
    Published
    21 June 2023
    View recommendations

    Sections for TA904

  5. Talimogene laherparepvec with pembrolizumab for treating unresectable or metastatic melanoma [ID3856]

    Discontinued Reference number: GID-TA10836

    Technology appraisal guidance
    Discontinued

  6. Pelareorep for treating metastatic malignant melanoma after previous therapy [ID941]

    Discontinued Reference number: GID-TA10686

    Technology appraisal guidance
    Discontinued

  7. Melanoma (metastatic) - paclitaxel albumin-bound nanoparticles (1st line) [ID570]

    Discontinued Reference number: GID-TAG440

    Technology appraisal guidance
    Discontinued

  8. Melanoma (advanced, unresectable, metastatic, NRAS mutation positive) - binimetinib [ID833]

    Discontinued Reference number: GID-TA10074

    Technology appraisal guidance
    Discontinued

  9. Nivolumab with ipilimumab for adjuvant treatment of completely resected stage III or IV melanoma [ID1610]

    Discontinued Reference number: GID-TA10499

    Technology appraisal guidance
    Discontinued

  10. Vemurafenib for treating resected BRAF V600 mutation-positive melanoma [ID1250]

    Discontinued Reference number: GID-TA10213

    Technology appraisal guidance
    Discontinued

  11. Atezolizumab with cobimetinib for untreated BRAF wild-type metastatic melanoma [ID1470]

    Discontinued Reference number: GID-TA10354

    Technology appraisal guidance
    Discontinued

  12. Relatlimab with nivolumab for treating advanced malignant melanoma after immunotherapy in people over 12 [ID1612]

    Discontinued Reference number: GID-TA10484

    Technology appraisal guidance
    Discontinued

  13. Masitinib for treating malignant melanoma that has a c-Kit juxtamembrane mutation [ID1082]

    Discontinued Reference number: GID-TA10627

    Technology appraisal guidance
    Discontinued

  14. Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma in people aged 12 to 17 [TSID11839]

    Awaiting development Reference number: GID-TA11276 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Atezolizumab with cobimetinib and vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma [ID1674]

    Discontinued Reference number: GID-TA10543

    Technology appraisal guidance
    Discontinued